drugset / Trial / NCT00421590

Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).

NCT00421590

Phase 2 Completed 38 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This study will assess the effect of concomitant antacid on the pharmacokinetics and pharmacodynamics of SMC021

Timeline

Start
2006-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject salmon calcitonin Unknown 0.8 mg Oral

Indications

No indication recorded.